Phase 1 N=31 Panitumumab in Children With Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)
Healthy
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs), by Treatment (Safety Analysis Set) — 2; 2; 5; 2 subjects
Phase 1 N=42 A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects
Healthy
Primary: The Effect of Food Timing (Fasting, Before Meal, and After Meal) on Pharmacokinetics (PK; AUC) of AZD0585 in Healthy Male Japanese. — 2.44; 2.66; 3.80; 0.299 milligram x…
Phase 1 N=24 A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets
Healthy
Primary: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Unchanged SYR-472 (SYR-472Z) — 2733; 2780 nanogram hour per…
Phase 1 N=27 A Study of EMD525797 in Solid Tumor Patients in Japan
Solid Tumor
Primary: Number of Subjects With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 subjects
Phase 1 N=20 Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers
Healthy
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 8.05; 8.21; 7.43; 16.71 μg/mL
Phase 1 N=38 Relative Bioavailability of Pimasertib in Cancer Patients
Neoplasms
Primary: Maximum Observed Plasma Concentration (Cmax) — 254.6; 314.1 nanogram per milliliter (ng/mL)
Phase 1 N=19 Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
Thrombocytopenia · Acute Radiation Syndrome
Primary: Maximum Tolerated Dose (MTD) of Eltrombopag — 300 mg/day
Phase 1 N=60 Trial of Yellow Fever Inactivated Vaccine
Yellow Fever
Primary: The Incidence and Severity of Adverse Events in Each Treatment Group in the Double-blind Treatment Period up to 42 Days Post-vaccination. — 13; 13; 2; 22 participants
Phase 1 N=26 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Relapsed Multiple Myeloma · End-stage Renal Disease
Primary: Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 — 563; 747 ng*h/mL
Phase 1 N=60 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)
Hepatitis C
Primary: Number of Participants Experiencing Adverse Events (AEs) — 5; 3; 4; 5 participants
Phase 1 N=12 Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters
Healthy
Primary: Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 20 Minutes Pre-dose — -19.779; -20.483 percent change
Phase 1 N=19 Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Obesity · Endothelial Dysfunction · Vitamin D Deficiency
Primary: Flow Mediated Dilatation (FMD) — 9.5; 10.4 percentage increase in BAD — p=0.59
Phase 1 N=74 Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
Healthy
Primary: AUC — 150607; 152208; 504584; 544818 (pg/ml)*hour
Phase 1 N=18 Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) of Caffeine After a Dose of PBT2 250mg — 32775 ng*hr/mL